- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02801890
Evaluation of Autologous Adipose Derived Mesenchymal Stromal Cells (AD-MSC) Transplantation in Ultra Filtration Failure (UFF)
Autologous AD-MSC Transplantation in Peritoneal Dialysis Patients With Ultra Filtration Failure and Evaluation of Cellular and Molecular Effects of Mesenchymal Stem Cell Infusion on Peritoneal Fibrosis
Peritoneal fibrosis may be occurred as a serious complication of peritoneal dialysis. It's the main factor of UFF that could lead to the Encapsulating Peritoneal Sclerosis (EPS). Using the potential features of MSCs in the treatment of fibrosis may offer new insights into reconstruction the damaged tissues. The project intends to transplant autologous MSCs to ten peritoneal dialysis patients with ultra-filtration failure. It's going to study infusion effects in clinical, cellular and molecular levels.
So in this trial, we will evaluate the effects of this intervention after intravenous injection of autologous adipose derived mesenchymal stem cells in 10 peritoneal dialysis patients with ultra filtration failure (UFF). Fifteen UFF patients are also considered as the control group. Then they will be followed 20, 45 and 90 days, and also 4 and 6 months after first injection.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Chronic kidney disease is defined as a reduced glomerular filtration rate, increased urinary albumin excretion, or both, and is an increasing public health issue. Prevalence is estimated to be 8-16% worldwide. Stage 5 CKD is often called end-stage kidney disease and usually means that the patient requires renal replacement therapy (RRT), which may involve a kidney transplant or a form of dialysis. One of the options in RRT is continuous ambulatory peritoneal dialysis (CAPD). CAPD is characterized by a continuous removal of extracellular fluid by peritoneal membrane. It should be noted that like any other peritoneal dialysis therapy, CAPD has Short or long-term complications and UFF is the most common functional disorder in which the peritoneal ultrafiltration membrane damaged.
This project intends to evaluate, the role of autologous mesenchymal stem cells in improvement of peritoneal membrane function in peritoneal dialysis patients who have ultrafiltration failure up to 6 months.
In this study, 10 male and female subjects who are on peritoneal dialysis for at least two years and have ultrafiltration failure with age range of 18 to 70 years will be enrolled. Patients will be selected from peritoneal dialysis patients attending the peritoneal dialysis ward of Dr. Shariati hospital. The main inclusion criteria is to be on peritoneal dialysis for at least last two years and having Ultrafiltration failure. After obtaining the consent form, a sample of fat tissue will be obtained by a general surgeon under sterilized condition from patients and then in the specialized lab, the mesenchymal stem cells will be separated and cultured to reach appropriate numbers (106/kg). The cells will be injected through peripheral vein in hospital setting. Patients will be followed-up (clinically and laboratory) at baseline and at week 3, week 6, month 3, month 4 and month 6. The clinical assessment and peritoneal function tests will be performed in each visit. Outcome measures: The main outcome measures that periodically will be assessed include: D/P cr, D/P urea, D0/D glucose, PET, KT/V urea, Glomerular filtration rate (GFR)
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
-
Tehran, Iran, Islamiska republiken
- Royan Institute
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- peritoneal dialysis for at least last two years and
- Ultrafiltration failure
- Both genders
- Age 18-70 years
- inform consent signing
Exclusion Criteria:
- Inability of patients to attend visits and regular testing
- Estimated lifetime less than one year
- Use of immunosuppressive drugs
- Pregnancy
- Malignancy
- Coagulative disorders
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: AD-MSC
The patients with ultra filtration failure (UFF) underwent AD-MSC injection.
|
Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
|
Placebo-jämförare: Placebo
The patients with ultra filtration failure (UFF) underwent Placebo injection.
|
Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Systemic infection
Tidsram: 6months
|
Evaluation the rate of systemic infection in patients with UFF after cell therapy.
|
6months
|
Hepatic failure
Tidsram: 6 months
|
Evaluation the rate of hepatic failure in patients with UFF after cell therapy.
|
6 months
|
Renal failure
Tidsram: 6 months
|
Evaluation the rate of renal failure in patients with UFF after cell therapy.
|
6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Ratio of 4-hour dialysate/plasma creatinine (D/P Cr).
Tidsram: 6 months
|
Evaluation the change of (D/P Cr) in patients with UFF after cell therapy.
|
6 months
|
Ratio of 4-hour dialysate/plasma urea (D/P urea )
Tidsram: 6 months
|
Evaluation the change of D/P in patients with UFF after cell therapy.
|
6 months
|
Ratio of dialysate glucose concentrations (D/D glucose )
Tidsram: 6 months
|
Evaluation the change of D/D glucose in patients with UFF after cell therapy.
|
6 months
|
peritoneal membrane transport function
Tidsram: 6 months
|
Assessment of peritoneal membrane transport function by peritoneal equilibration test (PET)
|
6 months
|
Glomerular filtration rate (GFR):
Tidsram: 6 months
|
Evaluation the change of Glomerular filtration rate (GFR) in patients with UFF after cell therapy.
|
6 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Soroosh Shekarchian, MD, Department of Regenerative Biomedicine at the Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
- Studierektor: Nasser Aghdami, MD,PhD, Department of Regenerative Biomedicine at the Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
- Studierektor: Gholamreza Pourmand, MD, Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Iran.
- Studierektor: Iraj Najafi, MD, Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Iran.
- Huvudutredare: Sudabeh Alatab, MD, Sudabeh
- Huvudutredare: Reza Moghadasali, PhD, Department of Regenerative Biomedicine at the Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- Royan-kidney-006
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Intravenous injection
-
Nova Scotia Health AuthorityAvslutad
-
Jiangsu HengRui Medicine Co., Ltd.Har inte rekryterat ännu
-
Bio-Thera SolutionsAvslutad
-
Jeffrey S HeierKato Pharmaceuticals, Inc.AvslutadVitreomakulär dragkraft | Vitreomakulär vidhäftning | Vitreomakulär fästeFörenta staterna
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Avslutad
-
GE HealthcareRekryteringOnkologi | Malign fast tumörNederländerna
-
Nuwacell Biotechnologies Co., Ltd.Har inte rekryterat ännu
-
Vifor Fresenius Medical Care Renal PharmaTigermed Consulting Co., LtdRekryteringSlutstadiet av njursjukdom vid hemodialysKina
-
Dermatology Cosmetic Laser Medical Associates of...SanofiIndragenUtmärgling | LipodystrofiFörenta staterna
-
Peking UniversityCARsgen Therapeutics Co., Ltd.RekryteringBukspottskörtelcancer | Gastriskt adenokarcinom | Gastroesofageal Junction AdenocarcinomaKina